Hideki Garren - 01 Nov 2022 Form 4 Insider Report for PROTHENA CORP PUBLIC LTD CO (PRTA)

Role: Chief Medical Officer
Signature: /s/ Michael Malecek, as attorney-in-fact for Hideki Garren
Issuer symbol: PRTA
Transactions as of: 01 Nov 2022
Net transactions value: -$147,975
Form type: 4
Filing time: 03 Nov 2022, 21:30:27 UTC
Previous filing: 05 Oct 2022
Next filing: 02 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PRTA	Ordinary Shares, par value $0.01 per share	Options Exercise	$99,600	+4,000		$24.90	4,000	01 Nov 2022	Direct
transaction	PRTA	Ordinary Shares, par value $0.01 per share	Sale	$215,683	-3,489	-87%	$61.82	511	01 Nov 2022	Direct	F1, F2
transaction	PRTA	Ordinary Shares, par value $0.01 per share	Sale	$31,892	-511	-100%	$62.41	0	01 Nov 2022	Direct	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PRTA	Stock Option (Right to Buy)	Options Exercise	$0	-4,000	-1.7%	$0.000000	226,000	01 Nov 2022	Ordinary Shares	4,000	$24.90	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2	The transaction was executed in multiple trades in prices ranging from $61.21 to $62.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 3 of this Form 4.
F3	The transaction was executed in multiple trades in prices ranging from $62.22 to $62.59, inclusive.
F4	The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on April 5, 2022, and vest and become exercisable with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.